Evidence map›Paper›PMID 33933118›Full record

ArticleRadiation oncology (London, England)2021

Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure.

J-J Stelmes, E Vu, V Grégoire, C Simon, E Clementel, J Kazmierska, W Grant, M Ozsahin, M Tomsej, L Vieillevigne and 6 more

Registry-linked trialAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02984410 (Phase III Study Assessing the "Best of" Radiotherapy Compared to the "Best of" Surgery), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02984410 naactive not recruitingnot on this map

Phase III Study Assessing the "Best of" Radiotherapy Compared to the "Best of" Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0-N1 Oropharyngeal, Supraglottic Carcinoma and With T1, N0 Hypopharyngeal Carcinoma

TypeinterventionalSponsorEuropean Organisation for Research and Treatment of Cancer - EORTCRan2017 to 2029Enrolled112ConditionsOropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell CarcinomaArmsIntensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

J-J Stelmes *Radiation Oncology Department, Oncology Institute of Southern Switzerland, Via Athos Gallino 12, 6500, Bellinzona, Switzerland. Jean-Jacques.Stelmes@eoc.ch.ORCID http://orcid.org/0000-0003-4887-6039
E Vu *Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
V GrégoireLyon University Hospital, Lyon, France.
C SimonLausanne University Hospital, Lausanne, Switzerland.
E Clementel *EORTC Headquarters, Brussels, Belgium.
J KazmierskaGreater Poland Cancer Center, Poznan, Poland.
W GrantGloucestershire Hospitals, NHS Foundation Trust, Gloucester, UK.
M OzsahinLausanne University Hospital, Lausanne, Switzerland.
M TomsejHospital of Charleroi, Charleroi, Belgium.
L VieillevigneInstitut Claudius Regaud IUCT, Toulouse, France.
C FortpiedEORTC Headquarters, Brussels, Belgium.
E C HurkmansCatharina Hospital, Eindhoven, The Netherlands.
A BranquinhoCentro Hospitalar Lisboa Norte, Lisbon, Portugal.
N AndratschkeUniversity Hospital Zurich, Zurich, Switzerland.
F ZimmermannUniversity Hospital of Basel, Basel, Switzerland.
D-C WeberUniversity Hospital of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe current phase III EORTC 1420 Best-of trial (NCT02984410) compares the swallowing function after transoral surgery versus intensity modulated radiotherapy (RT) in patients with early-stage carcinoma of the oropharynx, supraglottis and hypopharynx. We report the analysis of the Benchmark Case (BC) procedures before patient recruitment with special attention to dysphagia/aspiration related structures (DARS). MATERIALS AND

methodsSubmitted RT volumes and plans from participating centers were analyzed and compared against the gold-standard expert delineations and dose distributions. Descriptive analysis of protocol deviations was conducted. Mean Sorensen-Dice similarity index (mDSI) and Hausdorff distance (mHD) were applied to evaluate the inter-observer variability (IOV).

results65% (23/35) of the institutions needed more than one submission to achieve Quality assurance (RTQA) clearance. OAR volume delineations were the cause for rejection in 53% (40/76) of cases. IOV could be improved in 5 out of 12 OARs by more than 10 mm after resubmission (mHD). Despite this, final IOV for critical OARs in delineation remained significant among DARS by choosing an aleatory threshold of 0.7 (mDSI) and 15 mm (mHD).

conclusionsThis is to our knowledge the largest BC analysis among Head and neck RTQA programs performed in the framework of a prospective trial. Benchmarking identified non-common OARs and target delineations errors as the main source of deviations and IOV could be reduced in a significant number of cases after this process. Due to the substantial resources involved with benchmarking, future benchmark analyses should assess fully the impact on patients' clinical outcome.

Indexed as

BenchmarkingClinical Trials, Phase III as TopicHumansHypopharyngeal NeoplasmsObserver VariationOrgans at RiskOropharyngeal NeoplasmsPrognosisQuality Assurance, Health CareRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRetrospective StudiesSupraglottitisBenchmark caseEORTC 1420 Best-of trialOrgans at riskSwallowing

Identifiers

PMID33933118
PMCPMC8088557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.